Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: A cohort study

Annals of Internal Medicine

Volumn 154, Issue 5, 2011, Pages 310-318

  Clase, Catherine M ^a   Gao, Peggy ^b   Tobe, Sheldon W ^c   McQueen, Matthew J ^b   Grosshennig, Anja ^d   Teo, Koon K ^b   Yusuf, Salim ^b   Mann, Johannes F E ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Schwabing General Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

AGED; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; STROKE;

EID: 79952261740     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-5-201103010-00005     Document Type: Article

References (26)

1. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med. 2007;167: 2490-6. [PMID: 18071172]
2. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423-9. [PMID: 20124537]
3. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006; 17:2034-47. [PMID: 16738019]
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375:2073-81. [PMID: 20483451]
5. Canadian Organ Replacement Register. Annual report 2008. Ottawa: Canadian Institute for Health Information; 2010.
6. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. [PMID: 18378520]
7. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83. [PMID: 18757085]
8. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13:1034-9. [PMID: 11912263]
9. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930-7. [PMID: 8793803]
10. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-47. [PMID: 12859163]
11. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54:205-26. [PMID: 19577347]
12. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med. 2008;149:751-60. [PMID: 19017593]
13. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9. [PMID: 17182988]
14. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, et al; Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006;332:1426. [PMID: 16714328]
15. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006; 69:1264-71. [PMID: 16501489]
16. Vlek AL, van der Graaf Y, Spiering W, Algra A, Visseren FL; SMART study group. Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. J Intern Med. 2008;264:351-60. [PMID: 18522685]
17. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106: 1777-82. [PMID: 12356629]
18. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005; 112:969-75. [PMID: 16087792]
19. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-5. [PMID: 15210602]
20. Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med. 2007;167:1386-92. [PMID: 17620532]
21. Brantsma AH, Bakker SJ, de Zeeuw ZD, de Jong PE, Gansevoort RT; PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. 2008;19:1785-91. [PMID: 18525003]
22. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20:1069-77. [PMID: 19357254]
23. Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582-90. [PMID: 16899519]
24. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610-6. [PMID: 20424251]
25. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67: 2089-100. [PMID: 15882252]
26. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B; ONTARGET/ TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61. [PMID: 15215792]